Concert Completes THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543

May 23rd, 2022

Concert Pharmaceuticals has reported positive results in the first of two Phase 3 trials, THRIVE-AA1, to evaluate the efficacy and safety of CTP‑543 in adult patients with moderate to severe alopecia areata. A second Phase 3 trial, THRIVE-AA2, is ongoing.

CTP-543, an oral selective inhibitor of Janus kinases JAK1 and JAK2, is in clinical development for the treatment of moderate to severe alopecia areata in adults. CTP-543 is an investigational drug and has not been approved by the FDA or any regulatory authority for any use.


Back to Top